The EU Commission opens a formal investigation into possible anticompetitive conduct of a global pharmaceutical company in relation to a blockbuster multiple sclerosis medicine (Teva)

Antitrust: Commission opens formal investigation into possible anticompetitive conduct of Teva in relation to a blockbuster multiple sclerosis medicine* The European Commission has opened a formal antitrust investigation to assess whether the pharmaceutical company Teva has illegally delayed the market entry and uptake of medicines that compete with its blockbuster multiple sclerosis drug Copaxone. The Commission will investigate whether Teva has abused a dominant market position in breach of EU antitrust rules. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “Multiple sclerosis is a chronic illness affecting the daily lives of more than half a million Europeans requiring life-long treatment. Despite great efforts of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission opens a formal investigation into possible anticompetitive conduct of a global pharmaceutical company in relation to a blockbuster multiple sclerosis medicine (Teva), 4 March 2021, e-Competitions Intellectual property, Art. N° 99610

Visites 237

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues